The Beauty Health Company (SKIN) P/E Ratio History
Deep ValueTrading at -4.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2020–2022
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, The Beauty Health Company (SKIN) trades at a price-to-earnings ratio of -4.1x, with a stock price of $0.66 and trailing twelve-month earnings per share of $-0.05.
The current P/E is 110% below its 5-year average of 40.9x. Over the past five years, SKIN's P/E has ranged from a low of 0.2x to a high of 89.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Consumer Defensive sector median P/E of 18.8x, SKIN trades at a 122% discount to its sector peers. The sector includes 151 companies with P/E ratios ranging from 0.0x to 193.7x.
Relative to the broader market, SKIN trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SKIN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SKIN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SKIN P/E vs Peers
Suppliers, Durables and Specialty Retailers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 145.9 | 4.92 | -77% | |
| $3B | 18.9 | 0.56 | +2% | |
| $244M | 1.6Lowest | - | +208%Best | |
| $348M | 32.6 | - | -74% | |
| $849M | 9.4 | 0.94 | -36% | |
| $20B | 17.8 | 0.34Best | +1% | |
| $1B | 7.3 | 0.53 | +32% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SKIN Historical P/E Data (2020–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Dec 31 2022 | $9.10 | $0.28 | 32.7x | -20% |
| FY2022 Q3 | Sep 30 2022 | $11.79 | $0.13 | 89.9x | +120% |
| FY2020 Q4 | - | $11.31 | $51.57 | 0.2x | -99% |
Average P/E for displayed period: 40.9x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SKIN — Frequently Asked Questions
Quick answers to the most common questions about buying SKIN stock.
What is SKIN's P/E ratio?
The Beauty Health Company (SKIN) trailing twelve-month P/E ratio is -4.1x, based on TTM diluted EPS of $-0.05. The 5-year average P/E is 40.9x and the historical range spans 0.2x to 89.9x.
Is SKIN stock overvalued or undervalued?
SKIN trades at -4.1x P/E, below its 5-year average of 40.9x. At the 0th percentile of its historical range (0.2x–89.9x), the stock is priced at a discount to its own history.
Is SKIN stock expensive?
No, SKIN is not expensive on a historical basis. The current P/E of -4.1x is below the 5-year average of 40.9x and sits at the 0th percentile of its valuation range.
What is SKIN's historical P/E range?
Over the past 5 years, SKIN's P/E ratio has ranged from 0.2x to 89.9x, with a median of 32.7x and an average of 40.9x. The current P/E of -4.1x places the stock at the 0th percentile of this range. Full historical data spans 2020–2022.
How does SKIN's P/E compare to the S&P 500?
SKIN trades at -4.1x P/E versus the S&P 500 median of 24.4x. The 117% discount to the market suggests lower growth expectations or perceived higher risk.
How does SKIN's valuation compare to Consumer Defensive peers?
The Beauty Health Company P/E of -4.1x compares to the Consumer Defensive sector median of 18.8x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SKIN's PEG ratio?
SKIN PEG ratio is N/A, based on a P/E of -4.1x and EPS growth of 55.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SKIN's earnings yield?
SKIN earnings yield is N/A, the inverse of its -4.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.